Hibba Kurdi
Research Subjects
Hibba Kurdi has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
C Fielder Camm
Cardiology Research Fellow Keble College, University of Oxford, Parks Road, Oxford, OX1 3PG
3 shared publicationsAderonke Abiodun
University College London , 62 Huntley Street, London WC1E 6DD
2 shared publicationsBaskar Sekar
Cardiology Interventional Fellow Morriston Cardiac Centre, Morriston Hospital, Swansea, SA6 SNL
2 shared publicationsDerralynn Hughes
University College London , 62 Huntley Street, London WC1E 6DD
2 shared publicationsJessica Artico
University College London , 62 Huntley Street, London WC1E 6DD
2 shared publicationsSabrina Nordin
University of Glasgow and Queen Elizabeth University Hospital
2 shared publications
Latest Publications
- Open Access
- 14 March 2026
- Published by Elsevier in SSRN Electronic Journal
Mitochondrial Unfolded Protein Response Activation Associates with Phenotypes in Fabry Disease
Background: Fabry disease (FD) exhibits marked clinical heterogeneity that cannot be fully explained by residual α-galactosidase A activity. Mitochondrial dysfunction has been reported in FD, but the role of mitochondrial stress remains unexplored.Objective: To investigate whether activation of the mitochondrial unfolded protein response contributes to phenotypic variability and correlates with disease severity.Methods: We measured intracellular heat-shock protein 60 (Hsp60) by western blotting in peripheral blood mononuclear cells from 27 FD patients (14 males, 13 females). Serum fibroblast growth-factor-21 and growth differentiation-factor-15 were measured in 35 patients. Clinical outcomes included Mainz Severity Score Index, Age-Adjusting Severity Score, estimated glomerular filtration rate, and left-ventricular mass index (LVMI).Results: Hsp60 showed variability, with sex-specific associations. In males, higher Hsp60 correlated with lower LVMI (r²=-0.82, p=0.01) and preserved renal function in late-onset patients (r²=0.89, p=0.006). In females, higher Hsp60 associated with higher LVMI (r²=0.66, p=0.045) and greater clinical severity. Male patients had elevated growth differentiation-factor-15 vs controls (935 vs 559 pg/ml, p=0.002). Both mitokines correlated with age and disease severity.Conclusions: mitochondrial unfolded protein response activation exhibits sex- and genotype-specific patterns associated with disease severity, suggesting that mitochondrial stress contributes to phenotypic heterogeneity and may serve as biomarkers for treatment optimisation.
- 14 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMitochondrial Unfolded Protein Response Activation Associates with Phenotypes in Fabry Disease
Background: Fabry disease (FD) exhibits marked clinical heterogeneity that cannot be fully explained by residual α-galactosidase A activity. Mitochondrial dysfunction has been reported in FD, but the role of mitochondrial stress remains unexplored.Objective: To investigate whether activation of the mitochondrial unfolded protein response contributes to phenotypic variability and correlates with disease severity.Methods: We measured intracellular heat-shock protein 60 (Hsp60) by western blotting in peripheral blood mononuclear cells from 27 FD patients (14 males, 13 females). Serum fibroblast growth-factor-21 and growth differentiation-factor-15 were measured in 35 patients. Clinical outcomes included Mainz Severity Score Index, Age-Adjusting Severity Score, estimated glomerular filtration rate, and left-ventricular mass index (LVMI).Results: Hsp60 showed variability, with sex-specific associations. In males, higher Hsp60 correlated with lower LVMI (r²=-0.82, p=0.01) and preserved renal function in late-onset patients (r²=0.89, p=0.006). In females, higher Hsp60 associated with higher LVMI (r²=0.66, p=0.045) and greater clinical severity. Male patients had elevated growth differentiation-factor-15 vs controls (935 vs 559 pg/ml, p=0.002). Both mitokines correlated with age and disease severity.Conclusions: mitochondrial unfolded protein response activation exhibits sex- and genotype-specific patterns associated with disease severity, suggesting that mitochondrial stress contributes to phenotypic heterogeneity and may serve as biomarkers for treatment optimisation.
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (4) , 803-816
Reappraising cardiac function with myocardial contraction fraction: normal values, disease detection, and prognostication
Aims: Assessing cardiac function is critical for managing cardiovascular disease, guiding treatment, monitoring progression, and risk stratification. While left ventricular (LV) ejection fraction (LVEF) is firmly established, it has limitations. Myocardial contraction fraction (MCF)—the ratio of stroke volume to myocardial volume, is simple to compute without additional analysis and offers a promising alternative to LVEF. Methods and results: MCF was assessed across four datasets spanning healthy controls and chronic structural cardiac disease, with direct comparison to LVEF. Association between age, sex, and MCF were investigated in 3541 healthy subjects from the UK Biobank and sex-specific reference ranges derived. Several cohorts were recruited to investigate the discriminative power of MCF and LVEF between health and physiological adaption (n = 278 veteran athletes), pathological hypertrophy [hypertrophic cardiomyopathy, amyloid, Fabry, severe aortic stenosis (AS), and hypertension (HTN); n = 633], and dilatation [n = 103 dilated cardiomyopathy (DCM)]. Ability to track disease severity was assessed by looking at 41 558 subjects from the UK Biobank. Finally, prognostication was assessed on 1277 consecutive patients from an independent external dataset. All images were analysed using the same validated artificial intelligence algorithm. MCF varied with sex (mean MCF: 0.94 male; 1.1 female) but not age. Sex-specific reference ranges were established: [0.68–1.20] for male and [0.82–1.38] for female. MCF decreased in pathological disease (e.g. mean MCF: 0.72 HCM; 0.69 severe AS; 0.5 amyloid; 0.9 HTN) but there was no significant decrease in LVEF other than in amyloid (mean EF: 76% HCM; 64% severe AS; amyloid 56%; 65% HTN). Both MCF and ejection fraction (EF) decreased in DCM (EF 34%; MCF 0.58). MCF decreased with worsening HTN, whereas LVEF increased (P < 0.05). MCF had superior prognostic ability to LVEF (MCF vs. LVEF: HR = 0.772 vs. HR = 0.816; χ2 = 198 vs. χ2 = 151; P < 0.001). Conclusion: We established MCF reference ranges, showing superior performance for detecting early disease and tracking progression compared with LVEF. MCF offers enhanced prognostic utility, complementing established metrics of LV function.
- 22 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (4) , 803-816
Open AccessReappraising cardiac function with myocardial contraction fraction: normal values, disease detection, and prognostication
Aims: Assessing cardiac function is critical for managing cardiovascular disease, guiding treatment, monitoring progression, and risk stratification. While left ventricular (LV) ejection fraction (LVEF) is firmly established, it has limitations. Myocardial contraction fraction (MCF)—the ratio of stroke volume to myocardial volume, is simple to compute without additional analysis and offers a promising alternative to LVEF. Methods and results: MCF was assessed across four datasets spanning healthy controls and chronic structural cardiac disease, with direct comparison to LVEF. Association between age, sex, and MCF were investigated in 3541 healthy subjects from the UK Biobank and sex-specific reference ranges derived. Several cohorts were recruited to investigate the discriminative power of MCF and LVEF between health and physiological adaption (n = 278 veteran athletes), pathological hypertrophy [hypertrophic cardiomyopathy, amyloid, Fabry, severe aortic stenosis (AS), and hypertension (HTN); n = 633], and dilatation [n = 103 dilated cardiomyopathy (DCM)]. Ability to track disease severity was assessed by looking at 41 558 subjects from the UK Biobank. Finally, prognostication was assessed on 1277 consecutive patients from an independent external dataset. All images were analysed using the same validated artificial intelligence algorithm. MCF varied with sex (mean MCF: 0.94 male; 1.1 female) but not age. Sex-specific reference ranges were established: [0.68–1.20] for male and [0.82–1.38] for female. MCF decreased in pathological disease (e.g. mean MCF: 0.72 HCM; 0.69 severe AS; 0.5 amyloid; 0.9 HTN) but there was no significant decrease in LVEF other than in amyloid (mean EF: 76% HCM; 64% severe AS; amyloid 56%; 65% HTN). Both MCF and ejection fraction (EF) decreased in DCM (EF 34%; MCF 0.58). MCF decreased with worsening HTN, whereas LVEF increased (P < 0.05). MCF had superior prognostic ability to LVEF (MCF vs. LVEF: HR = 0.772 vs. HR = 0.816; χ2 = 198 vs. χ2 = 151; P < 0.001). Conclusion: We established MCF reference ranges, showing superior performance for detecting early disease and tracking progression compared with LVEF. MCF offers enhanced prognostic utility, complementing established metrics of LV function.
- 1 January 2025
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 32 (1)
Finding Fabry: a survey on missed opportunities for detection and diagnosis of Fabry disease in patients with LVH
Introduction Fabry disease is a rare X-chromosome-linked disorder that results from alpha-galactosidase A enzyme deficiency. It is broadly divided into classical (earlier onset, low enzyme activity) and non-classical (milder, later-onset and some residual activity). It is underdiagnosed despite the availability of ...
- 1 January 2025
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 32 (1)
Finding Fabry: a survey on missed opportunities for detection and diagnosis of Fabry disease in patients with LVH
Introduction Fabry disease is a rare X-chromosome-linked disorder that results from alpha-galactosidase A enzyme deficiency. It is broadly divided into classical (earlier onset, low enzyme activity) and non-classical (milder, later-onset and some residual activity). It is underdiagnosed despite the availability of ...
- 12 July 2024
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 100 (1190) , 956-958
The alternative fairytale: how personal history shapes identity and resilience in medicine
In “The Alternative Fairytale,” I explore my journey as a cardiology registrar/fellow, a path influenced deeply by my early displacement from war-torn Sudan. This piece reflects on the interplay between my professional choices and personal identity amidst the backdrop of a male-dominated field and societal expectations. It examines how my roots in a family that once fled conflict have shaped my approach to medicine—emphasizing community, empathy, and a leadership style that diverges from traditional norms. Through this narrative, I aim to redefine and help others to reflect on what success looks like in cardiology and medicine; advocating for diversity in leadership styles and highlight the importance of personal background in shaping professional paths.
- 12 July 2024
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 100 (1190) , 956-958
The alternative fairytale: how personal history shapes identity and resilience in medicine
In “The Alternative Fairytale,” I explore my journey as a cardiology registrar/fellow, a path influenced deeply by my early displacement from war-torn Sudan. This piece reflects on the interplay between my professional choices and personal identity amidst the backdrop of a male-dominated field and societal expectations. It examines how my roots in a family that once fled conflict have shaped my approach to medicine—emphasizing community, empathy, and a leadership style that diverges from traditional norms. Through this narrative, I aim to redefine and help others to reflect on what success looks like in cardiology and medicine; advocating for diversity in leadership styles and highlight the importance of personal background in shaping professional paths.
- 1 January 2024
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 31 (2) , 038
Navigating the research landscape in cardiology. Part 4: beyond the finish line
Introduction This four-part editorial series has been designed to navigate UK cardiology trainees and cardiovascular professionals through the pivotal stages of early career research. Beginning with an overview of how research can enhance a cardiologist’s career trajectory in Part 1,1 and moving through the ident ...
- 1 January 2024
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 31 (2) , 038
Navigating the research landscape in cardiology. Part 4: beyond the finish line
Introduction This four-part editorial series has been designed to navigate UK cardiology trainees and cardiovascular professionals through the pivotal stages of early career research. Beginning with an overview of how research can enhance a cardiologist’s career trajectory in Part 1,1 and moving through the ident ...
- 1 January 2024
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 31 (1) , 011
Navigating the research landscape in cardiology. Part 2: finding the right research
Introduction This editorial series aims to guide cardiology trainees and cardiovascular professionals through the intricate landscape of research. Our objective is to demystify the process, from understanding the role of research in cardiology training, to navigating the practicalities of securing the right researc ...
- 1 January 2024
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 31 (1) , 011
Navigating the research landscape in cardiology. Part 2: finding the right research
Introduction This editorial series aims to guide cardiology trainees and cardiovascular professionals through the intricate landscape of research. Our objective is to demystify the process, from understanding the role of research in cardiology training, to navigating the practicalities of securing the right researc ...
- 1 January 2023
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 30 (3) , 27
Navigating the research landscape in cardiology. Part 1: research – career necessity or bonus?
Introduction For those in cardiology training, finding research is often a daunting and multi-faceted process. The objective of this four-part series is to explore research in cardiology and will aim to serve as a reference point from finding the research, to applying for funding, straight through to the finish lin ...
- 1 January 2023
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 30 (3) , 27
Navigating the research landscape in cardiology. Part 1: research – career necessity or bonus?
Introduction For those in cardiology training, finding research is often a daunting and multi-faceted process. The objective of this four-part series is to explore research in cardiology and will aim to serve as a reference point from finding the research, to applying for funding, straight through to the finish lin ...
- 1 November 2021
- Vol. 28 (1) , 2
Lockdown cardiomyopathy: from a COVID-19 pandemic to a loneliness pandemic.
Social distancing/isolation is vital for infection control but can adversely impact on mental health. As the spread of COVID-19 is contained, mental health issues will surface with particular concerns for elderly, isolated populations. We present a case of Takotsubo cardiomyopathy related to lockdown anxiety.
- 1 November 2021
- Vol. 28 (1) , 2
Lockdown cardiomyopathy: from a COVID-19 pandemic to a loneliness pandemic.
Social distancing/isolation is vital for infection control but can adversely impact on mental health. As the spread of COVID-19 is contained, mental health issues will surface with particular concerns for elderly, isolated populations. We present a case of Takotsubo cardiomyopathy related to lockdown anxiety.
- 1 January 2021
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 28 (2) , 18
Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure
Patients with heart failure with reduced ejection fraction (HFrEF) who received the sodium-glucose co-transport 2 inhibitor, dapagliflozin, in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) study have a significant reduction in worsening heart failure (HF) and cardiovascular death. It is uncertain what proportion of patients admitted to a large regional cardiac centre with decompensated heart failure would be eligible for dapagliflozin post-discharge based on their characteristics at discharge. The DAPA-HF study criteria were retrospectively applied to a cohort of 521 consecutive patients referred to the inpatient HF service in a tertiary cardiac centre in South West Wales between April 2017 and April 2018. Inclusion criteria: left ventricular ejection fraction (LVEF) < 40%, New York Heart Association (NYHA) class II-IV symptoms and an elevated N-terminal pro-B-type naturietic peptide (NT-proBNP). Exclusion criteria: systolic blood pressure (SBP) < 95 mmHg, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2 or type 1 diabetes mellitus. We did not have complete NTproBNP data for the cohort, as it was not routinely measured at the time in our institute. There were 478 patients, mean age 78 ± 13 years, 57% male and 91% NYHA class II-IV symptoms, were included in the analysis. Of these, 247 patients had HFrEF, 219 (46%) patients met the inclusion criteria, 231 (48%) were excluded as LVEF was > 40%, and 48 (10%) were excluded with NYHA class I symptoms. Of the 219 patients who met the inclusion criteria, 13 (5.9%) had a SBP < 95 mmHg, 48 (22%) had eGFR < 30 ml/min/1.73 m2, leaving 136 (28.5% of total and 55% of those with HFrEF) who met DAPA-HF study criteria. In our study, 28.5% of all heart failure admissions and 55% of patients with HFrEF would be eligible for dapagliflozin post-discharge according to the DAPA-HF study entry criteria.
- 1 January 2021
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 28 (2) , 18
Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure
Patients with heart failure with reduced ejection fraction (HFrEF) who received the sodium-glucose co-transport 2 inhibitor, dapagliflozin, in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) study have a significant reduction in worsening heart failure (HF) and cardiovascular death. It is uncertain what proportion of patients admitted to a large regional cardiac centre with decompensated heart failure would be eligible for dapagliflozin post-discharge based on their characteristics at discharge. The DAPA-HF study criteria were retrospectively applied to a cohort of 521 consecutive patients referred to the inpatient HF service in a tertiary cardiac centre in South West Wales between April 2017 and April 2018. Inclusion criteria: left ventricular ejection fraction (LVEF) < 40%, New York Heart Association (NYHA) class II-IV symptoms and an elevated N-terminal pro-B-type naturietic peptide (NT-proBNP). Exclusion criteria: systolic blood pressure (SBP) < 95 mmHg, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2 or type 1 diabetes mellitus. We did not have complete NTproBNP data for the cohort, as it was not routinely measured at the time in our institute. There were 478 patients, mean age 78 ± 13 years, 57% male and 91% NYHA class II-IV symptoms, were included in the analysis. Of these, 247 patients had HFrEF, 219 (46%) patients met the inclusion criteria, 231 (48%) were excluded as LVEF was > 40%, and 48 (10%) were excluded with NYHA class I symptoms. Of the 219 patients who met the inclusion criteria, 13 (5.9%) had a SBP < 95 mmHg, 48 (22%) had eGFR < 30 ml/min/1.73 m2, leaving 136 (28.5% of total and 55% of those with HFrEF) who met DAPA-HF study criteria. In our study, 28.5% of all heart failure admissions and 55% of patients with HFrEF would be eligible for dapagliflozin post-discharge according to the DAPA-HF study entry criteria.
- Open Access
- 4 September 2020
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 51 (4) , 1120-1126
Massive pulmonary embolism in patients with extreme bleeding risk: a case series on the successful use of ultrasound-assisted, catheter directed thrombolysis in a district general hospital
Massive pulmonary embolism (PE), characterised by profound arterial hypotension, is a life-threatening emergency with a 90-day mortality of over 50%. Systemic thrombolysis can significantly reduce the risk of death or cardiovascular collapse in these patients, by around 50%, but these benefits are offset by a fivefold increased risk of intracranial haemorrhage and major bleeding, which may limit its use in patients at high risk of catastrophic haemorrhage. We describe a case series of 3 patients presenting with massive PE, each with extreme risk of bleeding and contra-indication to systemic thrombolysis, treated successfully with ultrasound-assisted, catheter directed thrombolysis (U-ACDT). Our experience of this novel technique using the EkoSonic Endovascular System (Ekos, BTG, London, UK) on carefully selected patients has demonstrated the potential to improve clinical status in shocked patients, with minimal bleed risk. There have been several clinical studies evaluating the Ekos system. Both the ULTIMA and SEATTLE II studies have shown significant reductions in RV/LV ratio by CT scanning when compared to standard anticoagulation in patients with intermediate-risk PE, with minimal bleeding complications. However, there is a pressing need for a randomised trial demonstrating improvement in robust clinical outcomes when comparing U-ACDT to simple anticoagulation. We believe that this case series adds new insight and highlights the potential of catheter directed thrombolysis in this high-risk patient cohort and consideration should be made to its use in cases where systemic thrombolysis is felt to be too high risk.
- 4 September 2020
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 51 (4) , 1120-1126
Open AccessMassive pulmonary embolism in patients with extreme bleeding risk: a case series on the successful use of ultrasound-assisted, catheter directed thrombolysis in a district general hospital
Massive pulmonary embolism (PE), characterised by profound arterial hypotension, is a life-threatening emergency with a 90-day mortality of over 50%. Systemic thrombolysis can significantly reduce the risk of death or cardiovascular collapse in these patients, by around 50%, but these benefits are offset by a fivefold increased risk of intracranial haemorrhage and major bleeding, which may limit its use in patients at high risk of catastrophic haemorrhage. We describe a case series of 3 patients presenting with massive PE, each with extreme risk of bleeding and contra-indication to systemic thrombolysis, treated successfully with ultrasound-assisted, catheter directed thrombolysis (U-ACDT). Our experience of this novel technique using the EkoSonic Endovascular System (Ekos, BTG, London, UK) on carefully selected patients has demonstrated the potential to improve clinical status in shocked patients, with minimal bleed risk. There have been several clinical studies evaluating the Ekos system. Both the ULTIMA and SEATTLE II studies have shown significant reductions in RV/LV ratio by CT scanning when compared to standard anticoagulation in patients with intermediate-risk PE, with minimal bleeding complications. However, there is a pressing need for a randomised trial demonstrating improvement in robust clinical outcomes when comparing U-ACDT to simple anticoagulation. We believe that this case series adds new insight and highlights the potential of catheter directed thrombolysis in this high-risk patient cohort and consideration should be made to its use in cases where systemic thrombolysis is felt to be too high risk.